SCHEMBL3479031

SCHEMBL3479031

CCCn1c(=O)[nH]c(=O)c2[nH]c(-c3ccc(Cl)nc3)nc21

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA2B P29275 12/20 0.67
ADORA2A P29274 8/20 0.67
ADORA1 P30542 3/20 0.49
HSD17B10 Q99714 2/20 0.49
ADORA3 P0DMS8 1/20 0.49
HPGD P15428 1/20 0.49
PDE4A P27815 1/20 0.49
BLM P54132 1/20 0.49
PDE4B Q07343 1/20 0.49
PDE4C Q08493 1/20 0.49
PDE4D Q08499 1/20 0.49
PDE3A Q14432 1/20 0.49
KDM4E B2RXH2 1/20 0.47
MEN1 O00255 1/20 0.47
ALDH1A1 P00352 1/20 0.47
CYP1A2 P05177 1/20 0.47
CYP3A4 P08684 1/20 0.47
CYP2C9 P11712 1/20 0.47
CYP2C19 P33261 1/20 0.47
KMT2A Q03164 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22105782 0.91 ADORA2B (0.54) ADORA2BADORA2AADORA1HSD17B10ADORA3
SCHEMBL6473698 0.89 ADORA2B (0.52) ADORA2BADORA2AADORA1HSD17B10ADORA3
SCHEMBL1001096 0.85 ADORA2B (0.67) ADORA2BADORA2AADORA1HSD17B10ADORA3
SCHEMBL7866286 0.82 ADORA2B (0.79) ADORA2BADORA2AADORA1HSD17B10ADORA3
SCHEMBL2686167 0.82 ADORA2B (0.68) ADORA2BADORA2AADORA1HSD17B10ADORA3
SCHEMBL7866612 0.81 ADORA2B (0.77) ADORA2BADORA2AADORA1HSD17B10ADORA3
SCHEMBL9765885 0.81 ADORA2B (1.00) ADORA2BADORA2AADORA1HSD17B10ADORA3
SCHEMBL24787659 0.79 ADORA2B (0.63) ADORA2BADORA2AADORA1HSD17B10ADORA3
SCHEMBL24786705 0.79 ADORA2B (0.63) ADORA2BADORA2AADORA1HSD17B10ADORA3
SCHEMBL1497273 0.78 ADORA2B (0.66) ADORA2BADORA2AADORA1HSD17B10ADORA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8501941-B2 Methods for the synthesis of unsymmetrical cycloakyl substituted xanthines DOGWOOD PHARMACEUTICALS, INC. (US) 2013-08-06 US disclosed
US-8420813-B2 Methods for the synthesis of unsymmetrical cycloalkyl substituted xanthines DOGWOOD PHARMACEUTICALS, INC. (US) 2013-04-16 US disclosed
US-20120226040-A1 METHODS FOR THE SYNTHESIS OF UNSYMMETRICAL CYCLOAKYL SUBSTITUTED XANTHINES DOGWOOD PHARMACEUTICALS, INC. (US) 2012-09-06 US disclosed
US-20100004445-A1 METHODS FOR THE SYNTHESIS OF UNSYMMETRICAL CYCLOALKYL SUBSTITUTED XANTHINES PGXHEALTH, LLC (US) 2010-01-07 US disclosed
US-7598379-B2 Methods for the synthesis of unsymmetrical cycloalkyl substituted xanthines PGX HEALTH, LLC (US) 2009-10-06 US disclosed
US-20070105821-A1 Methods for the synthesis of unsymmetrical cycloalkyl substituted xanthines ALLERGAN SALES, LLC 2007-05-10 US disclosed
WO-2006091936-A2 METHODS FOR THE SYNTHESIS OF UNSYMMETRICAL CYCLOALKYL SUBSTITUTED XANTHINES ADENOSINE THERAPEUTICS, LLC (US) 2006-08-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120226040-A1 METHODS FOR THE SYNTHESIS OF UNSYMMETRICAL CYCLOAKYL SUBSTITUTED XANTHINES ADORA2B, ADORA2A, ADORA3 ADORA2B 1/4885ADORA2A 2/4885ADORA1 4/4885
US-20070105821-A1 Methods for the synthesis of unsymmetrical cycloalkyl substituted xanthines ADORA2B, ADORA2A, ADORA3 ADORA2B 1/4885ADORA2A 2/4885ADORA1 4/4885
US-20100004445-A1 METHODS FOR THE SYNTHESIS OF UNSYMMETRICAL CYCLOALKYL SUBSTITUTED XANTHINES ADORA2B, ADORA2A, ADORA3 ADORA2B 1/4885ADORA2A 2/4885ADORA1 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.